Background
Methods
Setting
Study design
Pre-intervention phase
Intervention phase I
Intervention phase II
Data collection and outcome measures
Statistical analysis
All patients | Pre-intervention A | Intervention phase I B | Intervention phase II C | Crude p value |
p value after propensity score adjustment | ||||
---|---|---|---|---|---|---|---|---|---|
N = 436 |
N = 195 |
N = 699 | B vs. A | C vs. B | C vs. A | B vs. A | C vs. B | C vs. A | |
Source of sepsis, no. (%) | |||||||||
Pneumonia | 228 (52.3) | 93 (47.7) | 281 (40.2) | 0.29 | 0.06 | <0.0001 | 0.99 | 0.98 | 0.96 |
Urinary tract infection | 70 (16.1) | 28 (14.4) | 107 (15.3) | 0.59 | 0.74 | 0.74 | 0.78 | 0.90 | 0.38 |
Acute abdominal infection | 40 (9.2) | 8 (3.6) | 47 (6.7) | 0.03 | 0.18 | 0.13 | 0.05 | 0.37 | 0.17 |
Soft tissue infection | 8 (1.8) | 8 (4.1) | 32 (4.6) | 0.10 | 0.78 | 0.01 | 0.42 | 0.84 | 0.56 |
Other infections | 138 (31.7) | 68 (34.9) | 254 (36.3) | 0.43 | 0.71 | 0.11 | 0.92 | 0.60 | 0.48 |
Signs and symptoms, no. (%) | |||||||||
Hyperthermiaa
| 114 (26.2) | 52 (26.7) | 172 (24.6) | 0.89 | 0.56 | 0.56 | 0.81 | 0.15 | 0.47 |
Hypothermiaa
| 34 (7.8) | 6 (3.1) | 7 (1.0) | 0.02 | 0.04 | <0.0001 | 0.99 | 0.86 | 0.81 |
Acutely altered mental status | 157 (36.0) | 48 (24.6) | 59 (8.4) | 0.005 | <0.0001 | <0.0001 | 0.98 | 0.67 | 0.71 |
Chills and rigors | 11 (2.5) | 7 (3.6) | 2 (0.3) | 0.46 | 0.001 | 0.0006 | 0.55 | 0.0007 | 0.02 |
Tachycardiaa
| 354 (81.2) | 168 (86.2) | 624 (89.3) | 0.13 | 0.23 | 0.0001 | 0.76 | 0.44 | 0.49 |
Tachypneaa
| 368 (84.4) | 174 (89.2) | 583 (83.4) | 0.11 | 0.05 | 0.66 | 0.44 | 0.34 | 0.92 |
Hypotensiona
| 368 (84.4) | 111 (56.9) | 265 (37.9) | <0.0001 | <0.0001 | <0.0001 | 0.004 | 0.42 | <0.0001 |
Hypoxiaa
| 101 (23.2) | 79 (40.5) | 227 (32.5) | <0.0001 | 0.04 | 0.0008 | 0.94 | 0.96 | 0.99 |
Laboratory findings, no. (%) | |||||||||
Leukocytosisa
| 237 (54.4) | 85 (43.6) | 229 (32.8) | 0.01 | 0.005 | <0.0001 | 0.14 | 0.003 | <0.0001 |
Leukopeniaa
| 36 (8.3) | 6 (3.1) | 21 (3.0) | 0.02 | 0.96 | <0.0001 | 0.99 | 0.99 | 0.92 |
Increased creatininea
| 107 (24.5) | 4 (2.1) | 1 (0.1) | <0.0001 | 0.009 | <0.0001 | 0.97 | 0.99 | 0.68 |
Thrombocytopeniaa
| 40 (9.2) | 0 (0.0) | 1 (0.1) | <0.0001 | 1.0 | <0.0001 | 0.43 | 0.99 | 0.70 |
Hyperbilirubinemiaa
| 44 (10.1) | 1 (0.5) | 1 (0.1) | <0.0001 | 0.39 | <0.0001 | 0.82 | 0.94 | 0.68 |
Hyperlactatemiaa
| 168 (38.5) | 70 (35.9) | 320 (45.8) | 0.53 | 0.01 | 0.02 | 0.99 | 0.99 | 0.98 |
Coagulopathya
| 67 (15.4) | 2 (1.0) | 1 (0.1) | <0.0001 | 0.12 | <0.0001 | 0.87 | 0.86 | 0.67 |
Classification, no. (%) | |||||||||
Sepsis | 108 (24.8) | 99 (50.8) | 584 (83.6) | <0.0001 | <0.0001 | <0.0001 | 0.93 | 0.78 | 0.68 |
Septic shock | 328 (75.2) | 96 (49.2) | 115 (16.5) |
Results
Patients baseline characteristics
Propensity scores
Interventions during the course of treatment
Variable | Pre-intervention A | Intervention phase I B | Intervention phase II C |
p value |
p value after propensity scores adjustments | ||||
---|---|---|---|---|---|---|---|---|---|
All patients |
N = 436 |
N = 195 |
N = 699 | B vs. A | C vs. B | C vs. A | B vs. A | C vs. B | C vs. A |
Lactate measured at any time, no. (%) | 406 (93.1) | 191 (97.9) | 682 (97.6) | 0.01 | 1.0 | 0.0003 | 0.02 | 0.72 | 0.009 |
Time to lactate (h), mean ± SD | 9.3 ± 22.1 | 2.5 ± 5.3 | 1.1 ± 3.7 | <0.0001 | 0.0008 | <0.0001 | 0.002 | 0.0002 | <0.0001 |
Lactate (mmol/L), mean ± SD | 3.9 ± 3.6 | 3.3 ± 2.3 | 3.4 ± 5.5 | 0.01 | 0.93 | 0.03 | 0.76 | 0.28 | 0.26 |
Measure lactate within 6 h, no. (%) | 270 (61.9) | 168 (86.2) | 663 (94.9) | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
Blood culture obtained at any time, no. (%)a
| 238 (54.6) | 119/194 (61.3) | 592/679 (87.2) | 0.11 | <0.0001 | <0.0001 | 0.16 | <0.0001 | <0.0001 |
Time to blood culture (h), mean ± SD | 2.4 ± 6.7 | 0.9 ± 1.4 | 0.9 ± 2.5 | 0.001 | 0.94 | 0.0008 | 0.02 | 0.84 | 0.0001 |
Blood culture before antibiotics, no. (%) | 219 (50.2) | 116 (59.5) | 565 (80.8) | 0.02 | <0.0001 | <0.0001 | 0.10 | <0.0001 | <0.0001 |
Antibiotics administered at any time, no. (%)a
| 266/269 (98.9) | 136/137 (99.3) | 439/448 (98.0) | 1.0 | 0.47 | 0.55 | 0.97 | 0.45 | 0.87 |
Time to antibiotic administration (h), mean ± SD | 4.8 ± 6.7 | 3.0 ± 3.6 | 1.9 ± 3.3 | 0.0004 | 0.002 | <0.0001 | 0.002 | 0.002 | 0.01 |
Antibiotics within 3 h, no. (%) | 295 (67.7) | 149 (76.4) | 625 (89.4) | <0.0001 | <0.0001 | <0.0001 | 0.01 | 0.0001 | <0.0001 |
Patients with hypotension/lactate >4 mmol/L |
N = 406 |
N = 149 |
N = 361 | ||||||
---|---|---|---|---|---|---|---|---|---|
Fluids delivered at any time, no. (%)a
| 399 (98.3) | 148 (99.3) | 344 (95.3) | 0.69 | 0.02 | 0.02 | 0.51 | 0.15 | 0.51 |
MAP raised and remained >65 mmHg, no. (%) | 88/399 (22.1) | 53/148 (35.8) | 229/344 (67.8) | 0.001 | <0.0001 | <0.0001 | 0.02 | 0.50 | 0.09 |
Vasopressors administered, no. (%) | 299/311 (96.1) | 91/95 (95.8) | 101/115 (87.8) | 1.0 | 0.04 | 0.002 | 0.72 | 0.07 | 0.05 |
Fluids (≥20 mL/kg) and vasopressors in the first 6 h, no. (%) | 364/412 (88.4) | 144/153 (94.1) | 324/370 (87.6) | 0.04 | 0.03 | 0.74 | 0.04 | 0.08 | 0.85 |
Compliance with the 4 elements bundle | 84 (19.3) | 87 (44.6) | 485 (69.4) | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
Patients with persistent hypotension/lactate >4 mmol/L |
N = 333 |
N = 115 |
N = 209 | ||||||
---|---|---|---|---|---|---|---|---|---|
CVP ≥ 8 mmHg achieved, no. (%) | |||||||||
Within 6 h | 71/358 (19.8) | 24/121 (19.8) | 64/245 (26.1) | 0.99 | 0.18 | 0.07 | 0.47 | 0.0002 | <0.0001 |
Within 24 h | 190 (57.2) | 51 (44.4) | 98 (46.9) | 0.002 | 0.69 | <0.0001 | 0.06 | 0.004 | 0.66 |
After 24 h | 42 (12.7) | 6 (5.2) | 7 (3.4) | ||||||
Time to CVP (h), mean ± SD | 16.3 ± 21.8 | 11.3 ± 10.4 | 8.1 ± 9.5 | 0.01 | 0.05 | <0.0001 | 0.25 | 0.02 | 0.005 |
ScvO2 ≥ 70% achieved, no. (%) | |||||||||
Within 6 h | 65/358 (18.2) | 19/121 (15.7) | 56/245 (22.9) | 0.53 | 0.11 | 0.16 | 0.69 | <0.0001 | 0.0006 |
Within 24 h | 106 (31.9) | 26 (22.6) | 78 (37.3) | 0.03 | 0.57 | 0.006 | 0.003 | <0.0001 | 0.31 |
After 24 h | 37 (11.1) | 5 (4.4) | 7 (3.6) | ||||||
Time to ScvO2 (h) mean ± SD | 20.8 ± 52.1 | 9.8 ± 13.7 | 8.2 ± 12.7 | <0.0001 | <0.0001 | <0.0001 | 0.41 | 0.40 | 0.09 |
Outcomes
Variable | Pre-intervention A | Intervention phase I B | Intervention phase II C | Propensity scores adjusted OR or correlation coefficient* (95% CI, p value) | ||
---|---|---|---|---|---|---|
All patients |
N = 436 |
N = 195 |
N = 699 | B vs. A | C vs. B | C vs. A |
Hospital mortality, no. (%) | 208 (47.7) | 60 (30.8) | 118 (16.9) | 0.73 (0.48–1.09, 0.13) | 0.78 (0.51–1.17, 0.23) | 0.71 (0.58–0.85, 0.003) |
ICU LOS (days), mean ± SD | 13.3 ± 17.4 | 8.6 ± 8.3 | 5.1 ± 11.4 | −4.49 (−7.39 to −1.59, 0.002)* | −1.54 (−3.38 to 0.29, 0.09)* | −2.72 (−3.92 to −1.52, <0.0001)* |
Mechanical ventilation, no. (%) | 265 (60.8) | 54 (27.7) | 78 (11.2) | 0.33 (0.22–0.49, <0.0001) | 0.64 (0.41–0.99, 0.05) | 0.45 (0.37–0.55, <0.0001) |
ICU LOS among survivors (days), mean ± SD | 15.9 ± 19.5 | 11.9 ± 10.4 | 8.2 ± 13.8 | −5.88 (−11.44 to −0.22, 0.04)* | −1.05 (−5.22 to 3.10, 0.61)* | −3.55 (−6.13 to −0.98, 0.007)* |
Hospital LOS (days), mean ± SD | 29.3 ± 33.9 | 25.7 ± 40.9 | 15.3 ± 23.5 | −1.37 (−8.28 to 5.53, 0.70)* | −8.42 (−13.29 to −3.54, 0.0007)* | −5.35 (−7.76 to −2.94, <0.0001)* |
Hospital LOS among survivors (days), mean ± SD | 28.1 ± 30.8 | 24.7 ± 37.7 | 20.6 ± 28.6 | −1.76 (−12.09 to 8.57, 0.73)* | −6.22 (−16.9 to 4.48, 0.25)* | −3.45 (−7.83 to 0.92, 0.12)* |